Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70027 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Luca Potestio und 50 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Conjunctivitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real‐world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.
Objective
We aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate‐to‐severe AD treated with dupilumab or tralokinumab in a real‐life setting. Patients and Methods A multicenter, retrospective, observational study including adult patients with moderate‐to‐severe AD treated with dupilumab or tralokinumab for at least 16 weeks was carried out. Demographic, clinical, and therapeutic data were collected from 35 dermatological referral centers across Italy. Conjunctivitis incidence, severity, time to onset, and ophthalmologic management were analyzed and compared between treatment groups.
Results
A total of 6668 patients were included (5899 on dupilumab and 769 on tralokinumab). Conjunctivitis occurred in 10.76% of dupilumab‐treated and 12.61% of tralokinumab‐treated patients, with no statistically significant difference in overall incidence. However, time to onset was significantly shorter with tralokinumab than with dupilumab (15.3 ± 14.5 weeks vs. 35.5 ± 45.2 weeks, respectively; p < 0.0001). Ophthalmologic management strategies were similar between groups, mainly involving lubricants and corticosteroid‐based eye drops. Dupilumab‐treated patients more frequently discontinued or switched treatment due to conjunctivitis than tralokinumab patients (25.4% vs. 14.4%, respectively; p < 0.05).
Conclusions
Conjunctivitis represents a relatively frequent AE in patients with AD receiving dupilumab or tralokinumab. However, earlier onset of conjunctivitis with tralokinumab and higher discontinuation rates with dupilumab suggest differing tolerability profiles. Early recognition of ocular symptoms is essential, and dermatologists should promptly initiate supportive eye care and refer to ophthalmologists when appropriate to avoid unnecessary treatment interruptions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
- Department of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy.
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy.
- Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
ORCID-Profile: Luca Potestio, Cataldo Patruno, Simone Ribero, Francesca Barei, Laura Bonzano, Ilaria Trave, Bianca Maria Piraccini, Niccolò Gori, Ketty Peris, Mariateresa Rossi, Caterina Foti, Benedetta Tirone, Maria Esposito, Maria Concetta Fargnoli, Luca Stingeni, Flavia Manzo Margiotta, Ruggero Cascio Ingurgio, Emiliano Antiga, Claudio Marasca, Emanuela Martina, Maddalena Napolitano
Zitieren
APA
Potestio, L., Patruno, C., Del Gaudio, M., Ortoncelli, M., Ribero, S., Barei, F., Ferrucci, S. M., Bonzano, L., Trave, I., Guanti, M. B., Gurioli, C., Piraccini, B. M., Gori, N., Ippoliti, E., Peris, K., Grigolato, L., Rossi, M., Foti, C., Romita, P., …, & Napolitano, M. (2026). Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study. International Journal of Dermatology. https://doi.org/10.1111/ijd.70027
Vancouver
Potestio L, Patruno C, Del Gaudio M, Ortoncelli M, Ribero S, Barei F, et al. Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study. International Journal of Dermatology. 2026. doi:10.1111/ijd.70027
BibTeX
@article{Potestio2026,
author = {Potestio, Luca and Patruno, Cataldo and Del Gaudio, Marika and Ortoncelli, Michela and Ribero, Simone and Barei, Francesca and Ferrucci, Silvia Mariel and Bonzano, Laura and Trave, Ilaria and Guanti, Mario Bruno and Gurioli, Carlotta and Piraccini, Bianca Maria and Gori, Niccolò and Ippoliti, Elena and Peris, Ketty and Grigolato, Laura and Rossi, Mariateresa and Foti, Caterina and Romita, Paolo and Tirone, Benedetta and Nettis, Eustachio and Esposito, Maria and Fargnoli, Maria Concetta and Magnanimi, Lina Maria and Pezzolo, Elena and Hansel, Katharina and Stingeni, Luca and Satta, Rosanna and Mariano, Maria and Pigliacelli, Flavia and Margiotta, Flavia Manzo and Romanelli, Marco and Ingurgio, Ruggero Cascio and Costanzo, Antonio and Narcisi, Alessandra and Corazza, Monica and Antiga, Emiliano and Morrone, Pietro and Rubegni, Pietro and Calabrese, Laura and Lazzeri, Laura and Rubegni, Giovanni and Guarneri, Fabrizio and Zerbinati, Nicola and Carugno, Andrea and Puca, Rosa Valentina and Sarno, Oriele and Marasca, Claudio and Martina, Emanuela and di Vico, Francesca and Napolitano, Maddalena},
title = {Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70027}
}
EUVIMED